Physician profile
Brian Christopher Wolf
NPI 1437594363
$6,636.16
in general payments reported to CMS, 2019-2025
26 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $673 · 2022: $500 · 2023: $3,066 · 2024: $2,074 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,295 · Travel and Lodging: $2,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,295.34 |
| Travel and Lodging | $2,168.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,997.45 | 2021-2024 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, Intracept |
| Nevro Corp. | $1,308.38 | 2022-2024 | Senza |
| Curonix LLC | $471.20 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $419.64 | 2022-2023 | Sprint Pns System |
| Medtronic, INC. | $377.73 | 2022-2023 | Intellis Adaptivestim, Synchromedii, Cd Horizon Spinal System |
| Scilex Pharmaceuticals INC. | $207.96 | 2022-2025 | Ztlido |
| Ibsa Pharma INC. | $127.58 | 2022-2024 | Tirosint, Licart, Tirosint |
| Collegium Pharmaceutical, INC. | $126.36 | 2023-2025 | Belbuca |
| Grt US Holding, INC. | $92.49 | 2022 | |
| Globus Medical, INC. | $84.97 | 2025 | Senza, Vyrsa V1, Omnia |
| Lundbeck LLC | $53.70 | 2023-2025 | Vyepti |
| Abbott Laboratories | $51.53 | 2023-2025 | Eterna, Proclaim |
| Vertos Medical, INC. | $47.98 | 2023-2024 | Mild Device Kit |
| Bayer Healthcare Pharmaceuticals INC. | $44.65 | 2023 | |
| Novo Nordisk INC | $26.52 | 2024 | Rybelsus, Ozempic |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $24.30 | 2025 | |
| Bard Peripheral Vascular, INC. | $22.85 | 2025 | Venclose Maven Catheter |
| Pfizer INC. | $21.20 | 2025 | |
| Cardiva Medical, INC. | $19.31 | 2025 | Cardiva Vascade 6/7f Vcs |
| Relievant Medsystems, INC. | $19.14 | 2023 | Intracept |
| Azurity Pharmaceuticals, INC. | $16.76 | 2023 | Horizant |
| Averitas Pharma INC. | $16.29 | 2023 | Qutenza |
| Nalu Medical, INC. | $16.10 | 2023 | Nalu Neurostimulation System |
| Arbor Pharmaceuticals, INC. | $15.45 | 2022 | |
| Hikma Pharmaceuticals USA | $13.74 | 2022 | |
| Saluda Medical Americas, INC. | $12.88 | 2023 | Evoke Scs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.